IE 11 is not supported. For an optimal experience visit our site on another browser.
  • UP NEXT

    Pope Francis attempts to demystify Catholic Church in new memoir

    03:43
  • How buyers and sellers can save money with real estate ruling

    03:50
  • Iceland volcano erupts for 4th time since December

    00:38
  • Laken Riley's father speaks out: 'She was taken so early'

    02:40
  • First charter flight of Americans fleeing Haiti lands in Miami

    00:30
  • Target limits self-checkout to 10 items as more retailers shift policy

    03:07
  • Kate Middleton skips St. Patrick’s Day celebration amid questions

    05:24
  • Cougar attack victim speaks out after fight for her life

    01:19
  • Israel launches new raid on Gaza hospital as ceasefire talks resume

    02:13
  • Vladimir Putin wins his 5th presidential term in Russia

    03:07
  • Biden campaign slams Trump’s ‘bloodbath’ comment at rally

    02:19
  • Spring break shooting in Jacksonville leaves 1 dead, 2 injured

    01:58
  • Rats are ‘all high’ on marijuana after raiding police evidence room

    04:42
  • David E. Harris, first Black pilot for a major US airline, dies at 89

    02:10
  • What will happen to TikTok if the U.S. bans the app?

    04:46
  • Teams make final push for March Madness 2024

    02:57
  • Alexei Navalny supporters protest Russian presidential election

    02:02
  • Trump says there will be a ‘bloodbath’ if he isn’t reelected

    00:42
  • Chuck Schumer calls Netanyahu an 'obstacle to peace’

    01:34
  • White House weighs response if Israel invades Rafah

    01:39

Pfizer executive: ‘We’re confident’ about our vaccine being safe and effective for kids

04:44

Dr. Bill Gruber, Pfizer’s senior vice president of vaccine clinical research and development as well as a pediatrician, joins TODAY to talk about new data released from Pfizer showing its vaccine to be safe and effective for kids between 5 and 11. He says, “We intend to submit the data [to the FDA] by the end of the month.” He adds, “We’re hopeful and expectant that the FDA will approve the vaccine based on the data we have.” He also discusses an FDA panel’s recommendations about a third booster shot for adults.